Exhibit 99.1

	Dr. Reddy’s Laboratories Ltd.
	8-2-337, Road No. 3, Banjara Hills,
	Hyderabad - 500 034, Telangana,
	India.
	CIN: L85195TG1984PLC004507
	Tel  : +91 40 4900 2900
	Fax : +91 40 4900 2999
	Email : mail@drreddys.com
	www.drreddys.com

April 15, 2019

Corporate Relationship Department	National Stock Exchange of India Ltd.
BSE Limited	“Exchange Plaza”
Dalal Street, Fort	Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001	Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719	Fax Nos.: 022-26598120/ 26598237
Scrip Code: 500124	Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

This is to inform you that we have received the Establishment Inspection Report (BIR) from US FDA, for our Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad.

In February, 2019 this site has undergone an audit by the US FDA, wherein we were issued a Form 483 with 11 (eleven) observations. Based on our responses and follow up actions, the US FDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).

This is for your information.

With regards,

 

Vikas Sabharwal

Assistant Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)